Summit Therapeutics (SMMT) Operating Income (2017 - 2024)

Summit Therapeutics (SMMT) has reported Operating Income for 8 consecutive years, with -$65.6 million the latest figure, recorded in Q4 2024.

• Quarterly Operating Income fell 81.2% year-over-year to -$65.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$226.0 million (up 62.93% YoY) and the FY2024 annual result came in at -$226.0 million, up 62.93% from the prior year.
• Operating Income declined to -$65.6 million in Q4 2024 per SMMT's latest filing, from -$58.4 million in the prior quarter.
• Over the last five years, Operating Income for SMMT reached as high as -$9.3 million in Q1 2020 and fell as low as -$537.2 million in Q1 2023.
• A 5-year average of -$52.4 million and a median of -$20.4 million in 2022 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2023 — Operating Income sank 2324.2% — and 2024, when it surged 92.11%.
• Year by year, Operating Income stood at -$11.6 million in 2020, then sank by 125.4% to -$26.0 million in 2021, then increased by 22.07% to -$20.3 million in 2022, then sank by 78.38% to -$36.2 million in 2023, then plunged by 81.2% to -$65.6 million in 2024.
• According to Business Quant data, Operating Income over the past three periods registered -$65.6 million, -$58.4 million, and -$59.6 million for Q4 2024, Q3 2024, and Q2 2024 respectively.